




## Enantioselective Synthesis of *threo*- $\alpha,\beta$ -Dihydroxyphosphonates by Asymmetric Dihydroxylation of Vinylphosphonates. An Application to the Stereocontrolled Synthesis of (4*S*,5*S*)-4-Diethylphosphono-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane

Tsutomu Yokomatsu, Yoshinori Yoshida, Kenji Suemune,  
Takehiro Yamagishi, and Shiroshi Shibuya\*

Tokyo College of Pharmacy, 1432-1 Horinouchi, Hachioji, Tokyo 192-03, Japan

**Abstract:** The asymmetric dihydroxylation (AD) reaction of vinylphosphonates with AD-mix- $\alpha$  and - $\beta$  reagents was successfully applied to the enantioselective synthesis of *threo*- $\alpha,\beta$ -dihydroxyphosphonates.  $\beta$ -Aryl substituents on the vinyl phosphonates were found to be good directors for the reaction with respect to the yield and enantioselectivity. The utility of chiral  $\alpha,\beta$ -dihydroxyphosphonate **2c** was illustrated by the stereocontrolled synthesis of (4*S*,5*S*)-4-diethylphosphono-2,2-dimethyl-5-hydroxymethyl-1,3-dioxolane **6**, a potentially useful chiron for asymmetric synthesis of  $\alpha$ -heteroatom-substituted phosphonates.

The transformations of phosphate biomolecules to the phosphonate isosteres by replacement of the labile ester oxygen with a methylene group is one of the most interesting subjects in medicinal chemistry to elucidate their antimetabolite activities (Fig. 1).<sup>1</sup> A number of phosphonate analogues of phosphate biomolecules are known to show the expected activities.<sup>1</sup> Introductions of an additional functional group such as hydroxy- and fluoro substituents at the  $\alpha$ -position of the phosphonates are sometimes required to achieve sufficient biological activities<sup>2</sup> (Fig. 1). While the stereochemistry at  $\alpha$ -position in these substituted phosphonates should be important for the biological activities, little information on the biological effect of the three-dimensional structures is available due to a lack of efficient stereocontrolled methods for the synthesis of  $\alpha$ -heteroatom-substituted phosphonates.



Our interest in this area centers on the development of versatile phosphonic containing chirons for the synthesis of various  $\alpha$ -heteroatom-substituted phosphonic acid derivatives which would be of biological interest. The chiral glycol phosphonates **2** would constitute one of the most useful phosphonic chirons for this purpose, if efficient stereoselective syntheses of **2** were available and subsequently transformed to the suitably functionalized and protected forms such as **5** and **6**. Of various strategies for the stereoselective synthesis of **2**,

the catalytic asymmetric dihydroxylation (AD) strategy<sup>3</sup> of vinylphosphonates **1** would be the most desirable and efficient. In this paper we disclose the results on the osmium-catalyzed AD reaction of vinylphosphonates to yield chiral glycol phosphonates of high enantiomeric purity and an application to the synthesis of (4*S*,5*S*)-4-diethylphosphono-2,2-dimethyl-5-hydroxymethyl-1,3-dioxolane **6**, a useful phosphonic chiron for the stereocontrolled synthesis of  $\alpha$ -heteroatom-substituted phosphonic acid derivatives.

AD reactions of vinylphosphonates **1a-e**<sup>5</sup> were carried out at 25 °C for 48 h with AD-mix- $\alpha$  or - $\beta$  reagents<sup>9</sup> under the standard conditions<sup>3</sup> in the presence of additional potassium osmate (0.8 mol %) (Scheme 1). The results are summarized in Table 1. All reactions gave the desired *threo*- $\alpha$ ,  $\beta$ -dihydroxyphosphonates **2a-e**<sup>10,11</sup> in modest to good yields.

### Scheme 1




Table 1. AD reaction of vinylphosphonates **1a-e** with AD-mix- $\alpha$  and - $\beta$  reagents.

Entry	Reagent	R (2) <sup>a</sup>	Yield (%)	Ee (%) <sup>b</sup>	$[\alpha]_D^c$
1	AD-mix- $\alpha$	Me ( <b>2a</b> )	48	33	+3.73
2	AD-mix- $\alpha$	$\text{C}_6\text{H}_5$ ( <b>2b</b> )	42	91	+33.7
3	AD-mix- $\alpha$	4-MeOC <sub>6</sub> H <sub>4</sub> ( <b>2c</b> )	71	>95	+28.8
4	AD-mix- $\beta$	4-MeOC <sub>6</sub> H <sub>4</sub> ( <i>ent</i> - <b>2c</b> )	69	>98	-31.6
5	AD-mix- $\alpha$	$\text{PhCH}_2\text{O}(\text{CH}_2)_2$ ( <b>2d</b> ) <sup>d</sup>	30	44	-6.55
6	AD-mix- $\beta$	<i>t</i> -BuMe <sub>2</sub> SiOCH <sub>2</sub> ( <i>ent</i> - <b>2e</b> ) <sup>e</sup>	65	38	-8.25

<sup>a</sup> Obtained as oils. <sup>b</sup> Determined by NMR (<sup>1</sup>H and/or <sup>31</sup>P) analysis of the corresponding bis-MTPA esters derived from (+)- and (-)-MTPA. <sup>c</sup> Measured in MeOH (c 1.0) at 20 °C.


<sup>d</sup> Absolute stereochemistry was not determined. <sup>e</sup> Stereochemistry was determined by chemical correlation to **6**.<sup>12</sup>

While the AD reaction of vinylphosphonates **1a**, **1d**, and **1e** possessing alkyl substituents at the  $\beta$ -position proceeded with poor enantioselectivities in modest yields (entries 1, 5, and 6), remarkably high

enantioselectivities (>95% *ee*) were attained from the reactions with  $\beta$ -arylvinylphosphonates **1b**, **c** (entries 2-4); the *p*-methoxyphenyl group was found to be superior to a phenyl group as a director in terms of enantioselection and chemical yield (entries 2 vs 3).

The relative stereochemistry of **2c** was confirmed to be threo after conversion to the acetanides **3a** [2,2-dimethoxypropane, camphorsulfonic acid, benzene]. The dihedral angles between HCCP were measured with the lowest energy conformations of *trans*-**3c** and *cis*-**3c** produced by MOPAC calculations.<sup>13</sup> On the basis of these considerations and the phosphorus version of the Karplus equations,<sup>14</sup> a large vicinal proton-phosphorus coupling constant ( $^3J_{\text{PH}}=17.2$  Hz) is expected for *trans*-**3c**, while the small coupling constant ( $^3J_{\text{PH}}=1.7$  Hz) is assumed for *cis*-**3c** (Fig. 2). The close analysis of the  $^1\text{H-NMR}$  spectrum (300 MHz,  $\text{CDCl}_3$ ) of **3c** established the vicinal coupling constants to be 9.8 Hz, strongly suggesting its *trans* relative stereochemistry. Hydrogenolysis of **3b**, **c** over  $\text{Pd}(\text{OH})_2$  in MeOH gave  $\alpha$ -hydroxyphosphonates **4b**,  $[\alpha]_{\text{D}}^{20} +21.2$  (*c* 0.9,  $\text{CHCl}_3$ ), and **4c**,  $[\alpha]_{\text{D}}^{20} +17.4$  (*c* 0.6,  $\text{CHCl}_3$ ), respectively. Observed optical rotation of **4b** revealed that it was antipodal to that reported previously.<sup>15</sup> Thus, the absolute stereochemistry of **2c** was unambiguously established as 1*S*, 2*S*.

Fig. 2



Having established an efficient method for the stereoselective synthesis of **2c**, our attention was focussed on its transformations to **5** and **6**, useful phosphonic containing chirons possessing suitable functionalities. Oxidative degradation of the *p*-methoxyphenyl group in **3c** with  $\text{RuCl}_3\text{-NaIO}_4$  under the conditions of Martın,<sup>16</sup> followed by esterification with  $\text{CH}_2\text{N}_2$  gave the methyl ester **5**,<sup>10</sup>  $[\alpha]_{\text{D}}^{20} -26.2$  (*c* 1.0,  $\text{CHCl}_3$ ), as an oil in 95% yield. The observed vicinal proton-phosphorus coupling constant ( $^3J_{\text{PH}}=13.7$  Hz) is consistent with the calculated one ( $^3J_{\text{PH}}=17.4$  Hz) for *trans*-**5** (Fig. 2). Treatment of **5** with  $\text{NaBH}_4$  in MeOH selectively reduced the methyl ester to give alcohol **6**,<sup>10</sup>  $[\alpha]_{\text{D}}^{20} -15.5$  (*c* 1.0, MeOH), in 80% yield.

In conclusion we have developed an efficient method for stereoselective synthesis of phosphonic containing chirons **5** and **6** with practically useful levels of enantiomeric purity by an application of AD-reaction of vinylphosphonates. Further work on utility of **6** in the field of asymmetric synthesis of  $\alpha$ -heteroatom-substituted phosphonic bioisosteres of phosphate antimetabolites is in progress in our laboratory.

## References and Notes

- Hilderbrand, R. L. "The Role of Phosphonates in Living Systems", CRC press, Boca Raton, Florida, 1983; Engel, R. "Handbook of Organophosphorus Chemistry", Marcel Dekker, Inc., New York, 1992.
- Burke, Jr., T. R.; Smyth, M. S.; Nomizu, M.; Otaka, A.; Roller, P. P. *J. Org. Chem.*, **1993**, *58*, 1336; Thatcher, G. R.; Campbell, A. S. *J. Org. Chem.*, **1993**, *58*, 2272.; Blackburn, G. M. *Chem. Ind.* (London) **1981**, 134.

3. Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-S.; Kwong, H.-L.; Morikawa, K.; Wang, Z.-M.; Xu, D.; Zhang, X.-L. *J. Org. Chem.*, **1992**, *57*, 2768.
4. Engel, R. *Chem. Rev.* **1977**, *77*, 349; Mlotkowska, B.; Tropp, B.; Engel, R. *Carbohydrate Research*, **1983**, *117*, 95.
5. Vinylphosphonate **1a** was prepared by literature method.<sup>6</sup> Vinylphosphonates **1b-d** were prepared from the corresponding aldehydes by Horner-Emmons-Wadsworth (HEW) reaction [(EtO)<sub>2</sub>P(O)CH<sub>2</sub>P(O)(OEt)<sub>2</sub> / *n*-BuLi].<sup>7</sup> The silyloxyvinylphosphonates **1e** was synthesized by silylation of corresponding (*E*)-1-(diethylphosphono)-3-hydroxypropene.<sup>8</sup>
6. Horner, L.; Ertel, I.; Ruprecht, H.-D. Belovsky, O. *Chem. Ber.*, **1970**, *103*, 1582.
7. Moryanoff, B. F.; Reitz, A. B. *Chem. Rev.*, **1989**, *89*, 863.
8. Harde, C.; Neff, K.-H.; Nordhoff, E.; Gerbling, K.-P.; Laber, B.; Pohlenz, H.-D. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 273.
9. Purchased from Aldrich.
10. All new compounds gave satisfactory spectroscopic and analytical data.  
**2c**: an oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.34 (2H, d, *J*=6.8 Hz), 6.88 (2H, d, *J*=6.8 Hz), 5.08-5.02 (1H, m), 4.20-4.09 (4H, m), 3.99 (1H, ddd, *J*=3.5, 8.2, 8.2 Hz), 3.94-3.88 (1H, m), 3.79 (3H, s), 3.75-3.67 (1H, m), 1.32 (3H, t, *J*=6.8 Hz), 1.27 (3H, t, *J*=6.8 Hz); <sup>31</sup>P-NMR (CDCl<sub>3</sub>, 160 MHz) δ 22.56; MS *m/z* 340 (M<sup>+</sup>); IR (neat) 3344, 1246, 1029 cm<sup>-1</sup>. **3c**: an oil; [α]<sub>D</sub><sup>20</sup> +6.87 (*c* 1.0, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.37 (2H, d, *J*=8.8 Hz), 6.89 (2H, d, *J*=8.8 Hz), 5.20 (1H, dd, *J*=9.8, 9.8 Hz), 4.2-4.0 (4H, m), 3.99 (1H, dd, *J*=9.1, 2.4 Hz), 3.80 (3H, s), 1.56 (3H, s), 1.55 (3H, s), 1.24 (3H, t, *J*=7.1 Hz), 1.21 (3H, dd, *J*=7.1 Hz); <sup>31</sup>P-NMR (CDCl<sub>3</sub>, 160 MHz) δ 19.0; MS *m/z* 329 (M<sup>+</sup>-15); IR (neat) 3484, 1250, 1024 cm<sup>-1</sup>. **5**: an oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.74 (1H, dd, *J*=13.7, 7.6 Hz), 4.48 (1H, dd, *J*=7.6, 1.2 Hz), 4.3-4.1 (4H, m), 3.81 (3H, s), 1.52 (3H, s), 1.44 (3H, s), 1.35 (3H, t, *J*=7.0 Hz), 1.34 (3H, *J*=7.0 Hz); <sup>31</sup>P-NMR (CDCl<sub>3</sub>, 160 MHz) δ 18.0; MS *m/z* 297 (M<sup>+</sup>+1), 281 (M<sup>+</sup>-15); IR (neat) 1757, 1256, 1050 cm<sup>-1</sup>. **6**: an oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.4-4.3 (1H, m), 4.3-4.15 (4H, m), 4.09 (1H, dd, *J*=9.4, 2.5 Hz), 3.90 (1H, ddd, *J*=12.1, 3.9, 3.7 Hz), 3.74 (1H, ddd, *J*=12.1, 9.0, 3.3 Hz), 2.37 (1H, dd, *J*=9.0, 3.7 Hz), 1.46 (3H, s), 1.44 (3H, s), 1.37 (3H, t, *J*=7.1 Hz), 1.36 (3H, t, *J*=7.1 Hz); <sup>31</sup>P-NMR (CDCl<sub>3</sub>, 160 MHz) δ 19.7; IR (neat) 3407, 1647, 1240, 1024 cm<sup>-1</sup>.
11. Stereochemistry of **2a** was determined by its comparison with the authentic sample prepared through titanium-mediated threo-selective hydrophosphonylation of (*S*)-α-benzyloxypropionaldehyde, followed by debenylation: Yokomatsu, T.; Yoshida, Y.; Shibuya, S. *J. Org. Chem.* **1994**, in press.
12. Desilylation of *ent*-**3e** [*n*-Bu<sub>4</sub>NF / THF], derived from *ent*-**2e**, gave *ent*-**6**, [α]<sub>D</sub><sup>20</sup> +6.14 (*c* 1.0, MeOH), in quantitative yield.
13. Calculations were performed by MOPAC v 6.10 (PM 3) implemented in CAChe Worksystem (SONY/Tektronix Corporation) after MM 2 optimization of *trans*-**3c** and *cis*-**3c**.
14. Bentrude, W. G.; Setzer, W. N. In *Phosphorus-31 NMR Spectroscopy in Stereochemical Analysis*; Verkade, J. G.; Quin, L. D. Ed.; VHC: FL, 1987; pp 365-389.
15. Yokomatsu, T.; Shibuya, S. *Tetrahedron: Asymmetry* **1992**, *4*, 377.
16. Nuñez, M. T.; Martín, V. S. *J. Org. Chem.* **1990**, *55*, 1928.